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Background: Aim of the study was to investigate whether menstrual cycle length may be considered as a
surrogate measure of reproductive health, improving the accuracy of biochemical/sonographical ovarian reserve
test in estimating the reproductive chances of women referred to ART.
Methods: A retrospective-observational-study in Padua’ public tertiary level Centre was conducted. A total of 455
normo-ovulatory infertile women scheduled for their first fresh non-donor IVF/ICSI treatment. The mean menstrual cycle
length (MCL) during the preceding 6 months was calculated by physicians on the basis of information contained in our
electronic database (first day of menstrual cycle collected every month by telephonic communication by single
patients). We evaluated the relations between MCL, ovarian response to stimulation protocol, oocytes fertilization ratio,
ovarian sensitivity index (OSI) and pregnancy rate in different cohorts of patients according to the class of age and the
estimated ovarian reserve.
Results: In women younger than 35 years, MCL over 31 days may be associated with an increased risk of OHSS and
with a good OSI. In women older than 35 years, and particularly than 40 years, MCL shortening may be considered as a
marker of ovarian aging and may be associated with poor ovarian response, low OSI and reduced fertilization rate.
When AMH serum value is lower than 1.1 ng/ml in patients older than 40 years, MCL may help Clinicians discriminate
real from expected poor responders. Considering the pool of normoresponders, MCL was not correlated with
pregnancy rate while a positive association was found with patients’ age.
Conclusions: MCL diary is more predictive than chronological age in estimating ovarian biological age and response
to COH and it is more predictive than AMH in discriminating expected from real poor responders. In women older
than 35 years MCL shortening may be considered as a marker of ovarian aging while chronological age remains most
accurate parameter in predicting pregnancy.
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Epidemiological data clearly demonstrated that, within
and among women, menstrual cycles vary in length and
regularity and that often a correlation exists between
menstrual cycle characteristics and a variety of host, be-
havioural, occupational, and environmental factors [1].
However, few studies systematically examined whether
menstrual cycle features are related to the most direct
measures of reproductive health, fertility, and pregnancy
outcome. The menstrual pattern is commonly under-
stood to be fairly persistent within the individual, until
the late 40s, when cycles lengthen before menopause.
However, subtle gradual shortening of menstrual cycles
occurs in the late 30s in parallel with the increase of
FSH serum levels and the decrease of inhibin [2]. A
shorter MCL may thus indicate a more advanced ovarian
aging, which may proceed at a pace other than that of
chronological aging [1,3,4]. That is, although ovarian
aging is an inevitable process in all women, ovarian
reserve differs significantly between individuals of simi-
lar age.
In developed Countries, the amount of women bearing
children during the third and fourth decades of life is in-
creasing [3]. In this view, it is not difficult to remark that
many couples, experiencing age-related infertility due
to diminished ovarian reserve (OR), turn to assisted
reproduction techniques (ARTs).
In recent years, Clinicians involved in ARTs began fo-
cusing their attention and expending resources in defining
“pretreatment estimation chances” and “individualization
of treatment” in order to offer each woman the best treat-
ment customized to her unique characteristics [5].
Although the personalization of IVF treatment may lead
to improved patient compliance and clinical outcomes, it
is far from easy, and largely depends on the accuracy of
OR tests, usually performed by associating biochemical
anti-mullerian hormone (AMH) assay and antral follicle
count (AFC) [3,5-7]. The high accuracy of both AFC and
AMH in estimating biological ovarian age has lead Clini-
cians to use them (in association with basal FSH and
chronological age) to define the gonadotropin starting
dose, to estimate the ART success and to optimize costs
through an improvement in ovarian sensitivity index [8].
Unfortunately, a level of uncertainty remains concerning
the AMH assay as differences between laboratory mea-
surements persists. In addition, the absence of both a stan-
dardized measuring unit and a specific cut-off further
contributes to reducing its accuracy, particularly when the
values are located at the extremes of the Gaussian [9].
Women with extremely high or low AHM values are
usually defined as expected high or poor responders and
represent the category of patients in which cycle
cancellation rate is highest due to OHSS or absence of
ovarian response [5]. However, the overall accuracy ofAFC in these two cohorts (women estimated high or poor
responders) is lower than that of the general population
and often does not improve the AMH accuracy [10,11].
Recent evidences demonstrated that long MCLs are asso-
ciated with a greater number of antral follicle waves and
higher ovarian response to hormonal stimulation (this
seems to indicate higher reserve of primordial follicles in
the ovary) [12]. On the contrary, short MCLs are associ-
ated with poor response to ovarian hyperstimulation, a
markers of ovarian aging [13]. In consideration of the
above, it seems intuitive that the menstrual diary should
be routinely considered as a useful and low cost tool in es-
timating chances and improving reproductive outcome of
ART cycles, particularly when patient report any previous
ART cycle and their biological and chronological age do
not match [3,14].
Aim of the study was to investigate whether menstrual
cycle length may be considered as a surrogate measure
of reproductive health, improving the accuracy of bio-
chemical/sonographical ovarian reserve test in estimat-
ing the reproductive chances of women referred to ART.
Methods
We conducted a retrospective observational study on
normo-ovulatory infertile women scheduled for their
first fresh non-donor IVF/ICSI treatment at Assisted
Reproduction Unit of Gynecology and Obstetrics Clinic -
Department of Woman and Child Health- University of
Padua, between January 2011 and March 2014.
Our Study was defined exempt from IRB after consult-
ation with the local ethical committee (“Comitato Etico
per la Sperimentazione – Azienda Ospedaliera di Padova”).
Approval from the local institutional review board for
health sciences is not required for observational retro-
spective studies in which clinical management is not modi-
fied by the investigators. As usual in our unit, at admission
all patients gave written informed consent for the use of
their data in respect to the privacy law (Italian Law 675/
96). Signed informed consent was obtained from each
participant of this study.
We considered as eligible for the study women affected
by infertility, aged between 18 and 50 years, with BMI
ranging between 18 and 25, owning a personal menstrual
diary of the six months preceding the ART treatment.
MCL was defined as number of days between the first
day of bleeding until the day before the next bleeding
period. The mean MCL during the preceding 6 months
was calculated by physicians based on information re-
garding the beginning of menstrual cycle for all months
considered contained in and electronic database (col-
lected every month by telephonic communication by
single patients).
Cycles were excluded from the calculation if they were
subject to any kind of hormonal intervention. Patients
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cycle history could not be obtained.
We excluded patients with history of smoking in the
previous 12 months, deep endometriosis with elevated
CA125 serum value [15], abnormalities in karyotype, mu-
tations of the cystic fibrosis gene, acquired or inherited
thrombophilia and immunological disorders, previous
chemo and/or radio therapy for neoplasia, untreated
uterine diseases (such as endometrial polyps, sub mucous
myomas, intrauterine synechiae and/or uterine septus)
[16,17]. We also excluded patients who received low-dose
aspirin during treatment [18] and patients with personal
history of diabetes and thyroid disorders in order to avoid
a possible bias in evaluating the pregnancy rate [19,20].
Intervention
All patients were subjected to pre-treatment basal ovar-
ian reserve test by biochemical assays of FSH and AMH
levels in association with sonographic AFC [3].
According to pre-treatment ovarian reserve assessment,
all patients received the most adequate stimulation pro-
tocol (long agonist protocol and variable-scheme short
antagonist protocol) according to our Units Protocol. In
detail all patients were treated by rFSH and hMG (alone
or in combination) for ovarian stimulation, using a starting
dose, maintained for the first 5 days, of 100 IU, 225 IU
and 300 IU day in estimated high, normal and poor
responders, respectively. All women performed subcuta-
neous injection of 250 mg rhCG for ovulation induction
(when there were 2 or more follicles ≥16 mm in diameter
with accompanying follicles ≥12 mm and an adequate E2
response) and after 36 hours underwent oocyte retrieval.
Embryo transfer (ET) was performed 3 days after pick-up
with transfer of 3 embryo, when obtained, after selection
for quality [21]. All patients received high dose progester-
one supplementation (600 mg vaginally and 100 mg intra-
muscular for day) for luteal phase support until β-hCG
assay was performed 14 days after ET [22]. Clinical preg-
nancy was confirmed by ultrasonographic visualization of
one or more gestational sacs or definitive clinical signs of
pregnancy and ongoing pregnancy in the event of an
uncomplicated pregnancy over 12 gestational weeks.
Data collection
For all women we collected data regarding: age, BMI,
ovarian reserve test (b-FSH, b-AMH, b-AFC), mean
length of menstrual cycle in the six months prior to
ART cycle, total dose of gonadotropins administered
(IU), E2 at ovulation induction (nmol/L), endometrial
thickness at pick-up (mm), total number of oocytes,
number of MII oocytes, MII oocytes fertilization ratio
(considering 6 as the max number of oocytes fertilized,
in respect to Italian Law), number of obtained embryos,
clinical, ongoing pregnancy and miscarriage rate.We considered AGE_class_1 patients older than 40 years,
AGE_class_2 patients aged between 35–40 years, AGE_
class_3 patients aged between 26–34 years and AGE_
class_4 patients younger than 26 years.
We considered MCL_class_1 when the mean value of
the menstrual cycle was higher than 31 days, MCL_class_2
when ranged between 30–31 days, MCL_class_3 when
ranged between 28–29 days, MCL_class_4 when ranged
between 26–27 days and MCL_class_5 when less than
26 days.
We considered AMH cohort_1 when the AMH assay
showed a value ranging between 0.1-0.4 ng/ml, AMH
cohort_2 when the value ranged between 0.5-1.1 ng/ml
and AMH cohort_3 when the value was higher than
1.1 ng/ml.
Objectives
Primary objective was to evaluate whether a correlation
exists between the various classes of mean MCL and
number of MII oocytes, MII oocytes fertilization ratio
and OSI (oocytes recovered*1000/total dose of FSH) in
any considered subgroup of analyses [23].
Secondary objective was to detect if patients defined as
expected poor responders (subgroup of analyses) accord-
ing to Bologna Criteria (older than 40 years, AFC 5–7 fol-
licles and/or AMH 0.5–1.1 ng/ml) [24] showed different
ovarian response (mean number of MII oocytes) for each
cohort of AMH value in relation to the class of mean
MCL.
Finally, in estimated “normo-responder” patients we
assessed clinical pregnancy rate for fresh embryo transfer
in the different classes of MCL according to their class of
age.
Statistical analysis
Statistical analysis was performed by SPSS software
(Chicago,IL) for Windows version 19, applying para-
metric and non-parametric tests when appropriate. The
Kolmogorov–Smirnov test was used to assess the normal-
ity of distribution. Continuous variables were expressed as
absolute numbers, average ± standard deviation, and ana-
lyzed by Student-t test or Anova test when appropriate;
categorical variables were expressed as percentages and
analyzed through the χ2 test or the Fisher’s exact test,
when appropriate. Statistical significance was defined
as p values < 0.05.
Results
In the considered time frame, we collected data pertain-
ing to 455 eligible patients aged between 23 and 48 years
(mean value 36.42 ± 7.25). Data regarding general fea-
tures (BMI, bFSH, bAMH, bAFC, mean MCL), stratified
by age, were reported in detail in Table 1.
Table 1 General features of eligible patients stratified for
class of age
VARIABLES ALL PATIENTS [455]
[MEAN(±STANDARD
DEVIATION)]
AGE CLASS and PATIENT
NUMBER
[CLASS_1 (>40 years) 157]
[CLASS_2 (35–40 years) 115]
[CLASS_3 (26–34 years) 155]





























Table 2 Data about ovarian controlled hyperstimulation




AGE CLASS and PATIENT
NUMBER
[CLASS_1 (>40 years) 157]
[CLASS_2 (35–40 years) 115]
[CLASS_3 (26–34 years) 155]
[CLASS_4 (<26 years) 28]
[MEAN(±STANDARD
DEVIATION)]
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formed before the initiation of treatment, 185 patients
(40.7%) were expected poor-responders, 212 patients
(46.6%) normo-responders and 58 patients (12.7%) high-
responders. Regarding MCL diary, 21 patients (4.6%)
were classified as MCL_class_1, 73 patients (16.1%) as
MCL_class_2, 128 patients (28.1%) as MCL_class_3,
146 patients (32.1%) as MCL_class_4 and 87 patients
(19.1%) as MCL_class_5. Data about controlled ovarian
hyperstimulation cycles (FSH total dose, E2 max at
ovulation induction, endometrial thickness at pick-up,
total number of retrieved oocytes, number of MII oo-
cytes, oocytes fertilization ratio and OSI) were reported
in detail in Table 2.Among the 455 patients, 53 failed to receive embryo-
transfer for the following causes: in 7 patients (1.6%) no
oocytes were collected, in 24 patients (5.3%) no MII oo-
cytes were found, and in 22 patients (4.8%) no oocytes
were fertilised. Concerning the remaining 402 patients
(88.3%), 110 achieved a clinical pregnancy (27.4%) and, of
these, 62 patients (56.4%) reported an ongoing pregnancy.
The stratification of data according to patient’s class of
age, mean MCL class and mean number of retrieved MII
oocytes showed that a statistically significant difference
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40 years (mean MII oocytes: 6.1 in MCL_class_2, 4.6 in
MCL_class_3, 4.3 in MCL_class_4 and 1.3 in MCL_class_5
respectively) [p < 0.001]. Statistically significant differences
were also found in patients belonging to MCL_class_1 as
compared to those in MCL_class_2, MCL_class_3 and
MCL_class_4 aged less than 35 years (in both Age_class_3
and 4) [p < 0.05]. Within Age_class_2 only patients be-
longing to MCL_class_5 showed significant differences
compared to the remaining MCL classes (1.9 versus 5.2,
respectively) [p < 0.01]. On the contrary, the comparison
between MCL_class_2, 3 and 4 in Age_class_2, 3 and 4 did
not show any statistically significant differences, despite
better outcomes found in MCL_class_3 (Figure 1).
The stratification of data according to patient’s class of
age, mean MCL class and MII oocytes fertilization ratio
showed that a statistically significant difference exist
between the different MCL classes in patients older than
40 years (mean fertilization ratio: 86% in MCL_class_2,
77.5% in MCL_class_3, 71% in MCL_class_4 and 50.5%
in MCL_class_5, respectively) [p < 0.01]. Regarding
patients aged between 35 and 40 years, statistical differ-
ences were found only between MCL_class_5 (50.8%)Figure 1 The stratification of data according to patient’s class of age,
AGE_class_1: patients older than 40 years; AGE_class_2 patients aged betw
AGE_class_4 patients younger than 26 years) (MCL_class_1: >31 days, MCL
days, MCL_ class_5: <26 days.and MCL_class_2, 3 and 4 (mean value 79.2%) [p <
0.01]. No differences were found when comparing diff-
erent MCL classes in both Age_class_3 and 4 despite
MCL_class_1 showed a lower fertilization rate than
MCL_class_2, 3 and 4 (Figure 2).
The stratification of data according to patient’s class of
age, mean MCL class and OSI showed that a statistically
significant differences exists between MCL_class_1 and
MCL_class_2, 3 and 4 in patients younger than 35 years
(in both Age_class_3 and 4) [p < 0.001]. Considering
Age_class_3 and 4, MCL class_3 showed better OSI than
MCL class_2 ad 4 [Age class_3 p < 0.05 and Age class_4
p < 0.001, respectively]. Regarding Age_class_1 and 2,
OSI differed significantly in relation to the different
MCL classes, with a trend in reduction observed from
MCL_class_2 to MCL_class_5 [p < 0.05] (Figure 3).
Considering the cohort of patients defined as expected
poor-responders according to the Bologna Criteria, the
stratification of data according to MCL classes and AMH
cohorts in relation to mean MII oocytes retrieved showed
that no differences exist between MCL classes in AMH
cohort_3. Instead, significant differences were found in
AMH_cohort_2 between MCL_class_5 and MCL_class_3mean MCL class and mean number of MII oocytes retrieved.
een 35–40 years; AGE_class_3 patients aged between 26–34 years;
_ class_2: 30–31 days, MCL_ class_3: 28–29 days, MCL_ class_4: 26–27
Figure 2 The stratification of data according to patient’s class of age, mean MCL class and MII oocytes fertilization ratio. AGE_class_1:
patients older than 40 years; AGE_class_2 patients aged between 35–40 years; AGE_class_3 patients aged between 26–34 years; AGE_class_4
patients younger than 26 years) (MCL_class_1: >31 days, MCL_ class_2: 30–31 days, MCL_ class_3: 28–29 days, MCL_ class_4: 26–27 days,
MCL_ class_5: <26 days.
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significant worsening trend was observed when comparing
MCL_class_2 versus MCL_class_3 versus MCL_class_4
[p < 0.05] (Figure 4).
Finally, considering the cohort of patients estimated
normo-responders, the stratification of data according to
MCL classes, Age classes and clinical pregnancy rate for
fresh embryo transfer showed that no differences exist
between MCL classes and any Age class except for
MCL_class_2 (better ratio) and MCL_class_1 (worst ra-
tio) in very young patients (Age_class_4). On the con-
trary, as expected, a significant linear correlation was
found between low women’s age and pregnancy ratio
independent from the MCL classes [p < 0.05] (Figure 5).
Discussion
For most women, the regularity of the menstrual cycle is
characteristic of the major part of reproductive life. In
the few years following menarche and those preceding
menopause, many experience cycle irregularity. In fact,
the onset of such irregularity in later years is widely
regarded as the onset of the transition from regular cy-
cles to the final menses, or menopause [25].Decreasing follicle numbers, with a decreased number
of fully functioning granulosa cells, initially causes a
reduction in the secretion of inhibin B. The consequence
of which is an increase in FSH secretion in late luteal
and follicular phase, that may, in turn, lead to earlier
initiation of follicle development and to a shortened fol-
licular phase of continuing regular menstrual cycles. In-
tuitively, young women with high numbers of primordial
follicles may frequently experience menstrual cycles lon-
ger than 30 days [25].
Despite the fact that certain epigenetic factors have been
associated with abnormalities in menstrual cycle patterns
(age, BMI, sedentary lifestyle, intense activity, alcohol con-
sumption, smoking, caffeine consumption), aging alone is
able to influence MCL in the absence of known risk fac-
tors taking into account interpersonal differences some-
times insignificant, sometimes significant [26].
There is accumulating evidence that menstrual cycle
characteristics are the most direct measures of spontan-
eous reproductive health, fertility, and pregnancy out-
come in the general population [1].
Thus, it may be expected that a large portion of
women affected by subfertility/infertility and referring to
Figure 3 The stratification of data according to patient’s class of age, mean MCL class and OSI. AGE_class_1: patients older than 40 years;
AGE_class_2 patients aged between 35–40 years; AGE_class_3 patients aged between 26–34 years; AGE_class_4 patients younger than 26 years)
(MCL_class_1: >31 days, MCL_ class_2: 30–31 days, MCL_ class_3: 28–29 days, MCL_ class_4: 26–27 days, MCL_ class_5: <26 days.
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advanced age, premature ovarian failure and alteration
in diet and BMI.
Considering that ovarian stimulation is an integral part
of ARTs and, consequently, the responsiveness to go-
nadotropin stimulation is a factor which has important
implications on treatment, pre-treatment prediction of
ovarian response should be the most important param-
eter used to optimize treatment success and live birth
rate and minimize risks and costs [8].
Countless efforts have been made to establish the best
predictors of ovarian responsiveness, but the wide range of
ovarian reserve tests proposed suggest that no single test
provides a complete or sufficiently accurate estimate [10].
Very recently it has been internationally accepted that
the combination of AFC with basal AMH assay repre-
sents a good tool to assess “biological” ovarian age, and
therefore, to establish with high accuracy the gonado-
tropin starting dose and have a good predictability of
ART success while increasing both OSI and pregnancy
rate [5,6,8,9,11,24,27].
Disseldorp et al. in 2010 comparing the inter- and
intra-cycle stability of AFC and AMH demonstrated
that, despite AMH levels showed a positive correlationwith AFC levels, AMH seems to have less individual
intra- and inter-cycle variation than AFCs. Authors ex-
plained the higher stability of AMH measurements as-
suming that AMH levels are also determined by a
cohort of pre-antral or small antral follicles, whereas the
number of larger and visible antral follicles, expressed by
the AFC, may be more prone to short-term variation.
Possible explanations for a varying cohort of antral folli-
cles might be cyclic differences in decay or growth rate
which may depend on the presence of larger follicles in
the early follicular phase [28].
Unfortunately, in clinical practice clinicians often ob-
serve different ovarian responses in patients with com-
parable values of serum AMH, particularly when the
values are extremely low or high. Our intent, first in lit-
erature to our knowledge, was to determine whether
menstrual cycles can act as a surrogate measure of re-
productive health and may have a role in better defining
the reproductive chances of women referred to ART.
Our data clearly demonstrated that, when AMH serum
value is lower than 1.1 ng/ml and patients are estimated
poor responders, the ovarian response to hyperstimula-
tion is very different between individual patients and
strongly correlates with MCL. Patients with a history of
Figure 4 The stratification of data according to MCL classes and AMH cohorts in relation to mean MII oocytes retrieved (considering
the cohort of patients estimated poor-responders according to the Bologna Criteria). AGE_class_1: patients older than 40 years;
AGE_class_2 patients aged between 35–40 years; AGE_class_3 patients aged between 26–34 years; AGE_class_4 patients younger than 26 years)
(MCL_class_1: >31 days, MCL_ class_2: 30–31 days, MCL_ class_3: 28–29 days, MCL_ class_4: 26–27 days, MCL_ class_5: <26 days.
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ovarian response in accordance with MCL shortening.
In fact, in patients with AMH value less than 0.4 ng/ml
(cohort 1) an average of 3.5 oocytes per cycle were
collected in patients with a 30 day MCL length while
only1.2 oocytes per cycle were retrieved in those with
MCL length of 26 days.
In addition, our data showed that MCL correlated with
the fertilization rate of the MII oocytes retrieved, par-
ticularly in patients older than 35 years. In fact, consid-
ering patients older than 40 years (estimated poor
responder according to Bologna criteria) in which the
number of MII oocytes collected is usually low, in pa-
tients with MCL of about 30 days a fertilization rate of
almost 90% was observed compared to the 50% observed
in those with MCL less than 26 days. Interestingly, this
data, though it remains to be confirmed in a large scale
population, leads to hypothesize that MCL may be con-
sidered as a parameter of oocyte quality superior to
chronological age, as currently accepted [29].
However, patients’ age continues to maintain its lead-
ing role in assessing the chance of conceiving, since ourdata clearly demonstrated that clinical pregnancy was
associated with age class more than MCL class. Probably
MCL is a good mirror of “ovarian biological age” while
“chronological age” is one of the most important factors
affecting endometrial receptivity, probably the main factor
limiting the success of ART in patients over 35 years [29].
Our study also demonstrated that in younger and
expected normo-responder patients the MCL evaluation
can bring benefits: data about OSI clearly demonstrated
that even in patients aged between 26–34 years and in
patients younger than 26 years MCL longer than 31 days
was associated with an OSI of about 12.5 compared to
an OSI of about 5 when MCL was shorter than 30 days.
Interestingly, but not fully explained by our data, in
women younger than 35 years and with MCL ranging
between 26 and 30 days (estimated as a regular period
for general population) women with cycle length of
28 days showed better ovarian response and OSI than
those with MCL between 26–28 and 28–30 days. Prob-
ably in patients without luteal phase abnormalities, the
MCL deviating from 28 days (both in increasing and in
decreasing duration) may be considered as an indicator
Figure 5 The stratification of data according to MCL classes, Age classes and clinical pregnancy rate for fresh embryo transfer.
AGE_class_1: patients older than 40 years; AGE_class_2 patients aged between 35–40 years; AGE_class_3 patients aged between 26–34 years;
AGE_class_4 patients younger than 26 years) (MCL_class_1: >31 days, MCL_ class_2: 30–31 days, MCL_ class_3: 28–29 days, MCL_ class_4: 26–27
days, MCL_ class_5: <26 days).
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success of both singular (spontaneous cycles) and mul-
tiple follicular recruitment (assisted cycles).
According to the results of our study and awaiting
further validation, we strongly suggest to consider the
introduction in routine clinical practice of MCL evalu-
ation, in so much as we consider this parameter to be an
indicator of ovarian age superior to that of FSH and
chronological’ age. The large scale applicability and the
good accuracy (for any biological and chronological age)
of MCL in estimating ovarian response, OSI and
fertilization rate allows Clinicians to consider it as an
inexpensive good tool capable of improving the accuracy
of biochemical/sonographical ovarian reserve test and to
better estimate the ART success rate.
The strength of our data is due to the following: first
IVF cycle for all patients, strict inclusion criteria, medical
collection of menstrual diary for all months considered
(not self-reported by patients), good number of patients
for any class of “chronological” and “biological” age, singlecentre performance of AFC and ovarian stimulation
protocol, single laboratory (and units measure) for meas-
urement of AMH and other biochemical assays.
Unfortunately our study was not free of limitations:
retrospective collection of data, variability in ovarian
stimulation protocols (choosing the most appropriate for
each patients), use of both recombinant and purified
gonadotropins (alone or in combination), assessment of
oocytes fertilization ratio using 6 oocytes as a maximum
number to fertilize (according to the Italian law), lack of
data regarding the cumulative pregnancy rate considering
subsequent non-fresh gametes fertilization and embryo
transfers, absence of data regarding bleeding patterns of
single patients (qualitative and quantitative) may represent
a potential bias affecting our results.
In consideration of our study limitations represented
by the relatively small population size which was further
divided in sub-groups, we recommend caution in evalu-
ating our results. However the absence of cost and the
large scale implementation of MCL estimation prior to
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large-scale multicentre perspective trial.
Conclusion
Menstrual cycles may be considered as a surrogate meas-
ure of reproductive health and may have a role in improv-
ing the accuracy of biochemical/sonographical ovarian
reserve test in estimating the reproductive chances of
women referred to ART.
In women younger than 35 years, MCL over 31 days
may be associated with increased risk of OHSS and with
a good OSI.
In women older than 35 years, and particularly than
40 years, MCL shortening may be considered a marker
of ovarian aging and may be associated to poor ovarian
response, low OSI and reduced fertilization rate.
When AMH serum value is lower than 1.1 ng/ml and
patients older than 40 years, MCL may help Clinicians
to discriminate real to those expected poor responders.
MCL is a good inexpensive tool to estimate ovarian
age and response to hyperstimulation protocols, but the
chronological age remains most accurate in predicting
clinical pregnancy.
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